CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 11, 2012, Pages 519-524

  Zhou, Q ^a   Ruan, Z R ^a   Yuan, H ^a   Zeng, S ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

cytochrome p450; drug transporter; fluvastatin; pharmacokinetics; single nucleotide polymorphism

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; FLUINDOSTATIN; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; ABCB1 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; MULTIDRUG RESISTANCE PROTEIN; UNSPECIFIC MONOOXYGENASE;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CHINESE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; VALIDATION STUDY; ASIAN; GENETIC POLYMORPHISM; GENETICS;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; FATTY ACIDS, MONOUNSATURATED; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 84869114544     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1323696     Document Type: Article

References (15)

1. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther: 2006; 112 71 105
2. Kirchheiner J., Kudlicz D., Meisel C. et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther: 2003; 74 186 194
3. Li J., Volpe D. A., Wang Y. et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos: 2011; 39 1196 1202
4. Couvert P., Giral P., Dejager S. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics: 2008; 9 1217 1227
5. Bercovich D., Friedlander Y., Korem S. et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis: 2006; 185 97 107
6. Keskitalo J. E., Pasanen M. K., Neuvonen P. J. et al. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics: 2009; 10 1617 1624
7. TaqMan® SNP Genotyping Assays-Applied Biosystems. www3.appliedbiosystems.com
8. Xie H. G., Prasad H. C., Kim R. B. et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev: 2002; 54 1257 1270
9. Luo C. H., Wang A., Zhu R. H. et al. Gender specific association of CYP2C93 with hyperlipidaemia in Chinese. Br J Clin Pharmacol: 2005; 60 629 631
10. Keskitalo J. E., Kurkinen K. J., Neuvonen M. et al. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol: 2009; 68 207 213
11. Balram C., Sharma A., Sivathasan C. et al. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol: 2003; 56 78 83
12. Kalliokoski A., Neuvonen P. J., Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol: 2010; 107 775 781
13. He Y. J., Zhang W., Chen Y. et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta: 2009; 405 49 52
14. Niemi M., Pasanen M. K., Neuvonen P. J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther: 2006; 80 356 366
15. Zhang W., Yu B. N., He Y. J. et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta: 2006; 373 99 103